Correlation between 25-hydroxy vitamin D levels and COVID-19 severity in pregnant women: a cross-sectional study
Seven et al.
, Correlation between 25-hydroxy vitamin D levels and COVID-19 severity in pregnant women: a cross-sectional..
, The Journal of Maternal-Fetal & Neonatal Medicine, doi:10.1080/14767058.2021.2005564
Prospective study of 403 pregnant COVID+ hospitalized women in Turkey, showing higher risk of severe disease or poor prognostic factors with vitamin D deficiency.
risk of severe disease or poor prognostic factor, 46.5% lower, RR 0.53, p = 0.006, cutoff 14.5ng/ml, inverted to make RR<1 favor high D levels (≥14.5ng/ml).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Seven et al., 23 Nov 2021, prospective, Turkey, peer-reviewed, 6 authors, study period September 2020 - November 2020.
Abstract: The Journal of Maternal-Fetal & Neonatal Medicine
ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/ijmf20
Correlation between 25-hydroxy vitamin D levels
and COVID-19 severity in pregnant women: a
B. Seven, O. Gunduz, A. S. Ozgu-Erdinc, Dilek Sahin, O. Moraloglu Tekin & H.
To cite this article: B. Seven, O. Gunduz, A. S. Ozgu-Erdinc, Dilek Sahin, O. Moraloglu Tekin &
H. L. Keskin (2021): Correlation between 25-hydroxy vitamin D levels and COVID-19 severity in
pregnant women: a cross-sectional study, The Journal of Maternal-Fetal & Neonatal Medicine, DOI:
To link to this article: https://doi.org/10.1080/14767058.2021.2005564
Published online: 23 Nov 2021.
Submit your article to this journal
Article views: 52
View related articles
View Crossmark data
Full Terms & Conditions of access and use can be found at
THE JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
Correlation between 25-hydroxy vitamin D levels and COVID-19 severity in
pregnant women: a cross-sectional study
, O. Gunduza
, A. S. Ozgu-Erdinca,b
, Dilek Sahina,b
, O. Moraloglu Tekina,b
and H. L.
Department of Ob&Gyn, Ankara City Hospital, Ankara, Turkey; bDepartment of Ob&Gyn, University of Health Sciences, Turkey
Objective: To evaluate the relationship between 25-hydroxy vitamin D (25(OH)D) levels and disease severity in hospitalized COVID-19 positive pregnant women
Methods: The COVID-19 (þ) pregnant women (confirmed by PCR test) were classified as asymptomatic, mild symptomatic, and severe disease according to their symptoms and laboratory
results. Severe COVID-19 criteria were respiratory symptoms and/or findings. The following
laboratory results were considered as poor prognostic factors: the number of lymphocytes
<800/ml and/or CRP value >10 times the upper limit of the normal range and/or ferritin value
>500 ng/ml and/or D-Dimer value >1000 mg/l. The patients were divided into two groups;
asymptomatic or mild symptomatic group (Group 1), and severe disease and/or poor prognostic
factor group (Group 2). The 25(OH)D levels were compared between groups. ROC curve analysis
was used to analyze the cutoff value for vitamin D to predict the severity of COVID-19.
Results: 25(OH)D levels were found to be statistically significantly lower in group 2 (15.5 (10.25)
ng/ml in Group 1, 13 (12) ng/ml in Group 2, p ¼ .010). The 25(OH)D level under 14.5 ng/ml was
associated with severe COVID-19 and/or poor prognostic factors (p ¼ .010). The risk of severe
COVID-19 and/or having poor prognostic factors was 1.87 times higher among pregnant women
who had 25(OH)D levels below 14.5 ng/ml. This value was found to have 54.1% sensitivity and
61.3% specificity in predicting severe COVID-19 and/or poor prognostic laboratory findings in
Conclusion: There is a relationship between vitamin D status and the severity of COVID-19 in
pregnant women. During the pandemic period, vitamin D supplementation for pregnant women
should gain more importance.
Received 10 June 2021
Revised 19 September 2021
Accepted 9 November 2021
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.